Trials / Recruiting
RecruitingNCT07180082
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer: a Prospective, Randomized, Controlled, Multicentre Clinical Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 186 (estimated)
- Sponsor
- Wenjin Yin · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyrotinib | anti-HER2 tyrosine kinase inhibitor |
Timeline
- Start date
- 2025-08-28
- Primary completion
- 2028-09-01
- Completion
- 2029-09-01
- First posted
- 2025-09-18
- Last updated
- 2025-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07180082. Inclusion in this directory is not an endorsement.